Sulphonyl urea derivatives as NLRP3 inflammasome modulators
US12012397B2 · kind B2 · utility
0Cited by
24References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 17, 2022 |
| Grant date | Jun 18, 2024 |
| Priority date | — |
| Expiry date | Oct 17, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.